FSME IMMUN NEW Follow-Up to Study 205 in Children Aged 6 to 16 Years
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to investigate the safety and immunogenicity of the third vaccination with one of three different concentrations of a TBE vaccine in all volunteers who completed two vaccinations in one of the three treatment groups of Baxter study 205 (safety and immunogenicity of two vaccinations with FSME IMMUN NEW in healthy volunteers aged 6 to 16 years).
| Condition | Intervention | Phase |
|---|---|---|
|
Encephalitis, Tick-Borne |
Biological: Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind |
| Official Title: | Follow-Up Study to Investigate the Safety and Immunogenicity of a Third Vaccination With Three Different Antigen Concentrations of FSME IMMUN NEW in Children Aged 6 to 16 Years |
Eligibility| Ages Eligible for Study: | 6 Years to 16 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion criteria:
All volunteers who participated in Baxter study 205 and received two vaccinations will be invited to participate. Male and female children will be eligible for participation in this study if:
- They received two vaccinations with one of the three different dosages of FSME IMMUN NEW during the course of Baxter study 205
- They and/or their legal guardian understand the nature of the study, agree to its provisions and give written informed consent
Exclusion Criteria:
There are no specific exclusion criteria for this study entry. However volunteers will be assessed for eligibility to receive a third vaccination.
Volunteers will be excluded from vaccination and consecutive visits in this study if they:
- Are not clinically healthy, (i. e. the physician would have reservations vaccinating with FSME IMMUN NEW outside the scope of a clinical trial)
- Have already been administered a third TBE vaccination elsewhere after the two vaccinations in Baxter study 205
- Have had an allergic reaction to one of the components of the vaccine since the last vaccination in Baxter study 205
- Suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids, chemotherapeutics) that can be expected to influence immunological functions
- Have received banked human blood or immunoglobulins within one month of study entry
- Are known to be HIV positive (a special HIV test is not required for the purpose of the study) since the last visit of Baxter study 205
- Have had a vaccination against yellow fever and / or Japanese B-encephalitis since the last visit in Baxter study 205
- Had received an investigational new drug within 6 weeks prior to study start
- If female and capable of bearing children – have a positive pregnancy test at the first medical examination
Contacts and Locations| Germany | |
| Neuschwanstein Strasse 5 | |
| Augsburg, Germany, D-86163 | |
| Marktplatz 33 | |
| Bad Saulgau, Germany, D-88348 | |
| Hauptstrasse 9 | |
| Bietigheim-Bissingen, Germany, D-74321 | |
| Salzgasse 11 | |
| Calw, Germany, D-75365 | |
| Mohrenstrasse 8 | |
| Coburg, Germany, D-96450 | |
| Bahnhofstrasse 1 | |
| Elzach, Germany, D-79215 | |
| Rheinstrasse 1a | |
| Ettenheim, Germany, D-77955 | |
| Peter-Seifert Strasse 5 | |
| Gersfeld, Germany, D-36129 | |
| Solothumer Strasse 2 | |
| Heilbronn, Germany, D-74072 | |
| Hauptstrasse 240 | |
| Kehl, Germany, D-77694 | |
| Schwarzwald Strasse 20 | |
| Kirchzarten, Germany, D-79199 | |
| Altoettinger Strasse 3 | |
| Landsberg, Germany, D-86899 | |
| Rastatter Strasse 7 | |
| Mannheim-Secken, Germany, 68239 | |
| Wilhelmstrasse 25 | |
| Metzingen, Germany, D-72555 | |
| Dohmbuehler Strasse 8 | |
| Nuernberg, Germany, D-90449 | |
| Wilhelmstrasse 7 | |
| Offenburg, Germany, D-77654 | |
| Berneckstrasse 19 | |
| Schramberg, Germany, D-78713 | |
| Hauptstrasse 11 | |
| Tegernsee, Germany, D-83681 | |
| Broner Platz 6 | |
| Weingarten, Germany, D-88250 | |
| Principal Investigator: | Baxter BioScience Investigator | Baxter Healthcare Corporation |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00161889 History of Changes |
| Other Study ID Numbers: | 207 |
| Study First Received: | September 8, 2005 |
| Last Updated: | June 12, 2006 |
| Health Authority: | Germany: Paul-Ehrlich-Institut |
Additional relevant MeSH terms:
|
Encephalitis, Tick-Borne Encephalitis Central Nervous System Viral Diseases Virus Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Central Nervous System Infections |
Encephalitis, Arbovirus Arbovirus Infections Tick-Borne Diseases Encephalitis, Viral RNA Virus Infections Flavivirus Infections Flaviviridae Infections |
ClinicalTrials.gov processed this record on May 23, 2013